Methyclothiazide

Research use only, not for human use.

Methyclothiazide is a substituted benzothiadiazide, used to treat high blood pressure and fluid retention caused by various conditions including heart disease.

Methyclothiazide is a thiazide diuretic with properties similar to those of Hydrochlorothiazide.

Methyclothiazide (0-100 μM) induces endothelium-dependent inhibition of the vasoconstrictor responses to NE and AVP only in aortas from SHR, and the maximal vasoconstrictive effect of Norepinephrine (HY-13715) and arginine vasopressin (AVP) is decreased by 59% and 32.3 %, respectively. Methyclothiazide (0-100 μM) induces inhibitory effect on the contractile response to Norepinephrine (HY-13715) is abolished by N-nitro-L-arginine (NOLA) but not indomethacin. Methyclothiazide (100 μM) affects the vascular responses to extracellular Ca2+ under high-K+ depolarizing conditions. It can reduce Ca2+ contracture in a high-K+, Ca2+-free solution. The maximal contracture is reduced by 90.4%.

——

Methyclothiazide | Aquatensen | Duretic | Enduron

Others

Other Targets

Others

Others-Field

——

135-07-9

360.24

C9H11Cl2N3O4S2

>98% (HPLC)

In Vitro:?DMSO : 72 mg/mL (199.87 mM)

CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O

6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide

(-20℃)

With Ice Pack

≥ 2 years